Obesity Journal Editor Cashes In on Weight-Loss Drug Research; $1.2 Million Raises Ethical Questions

Associate Editor-in-Chief of the journal Obesity Donna Ryan is facing scrutiny following revelations that she received substantial sums from pharma, presumably for her praise of weight-loss drugs. Some of her pharma-positive articles acknowledge the conflict of interest while others pointedly avoid it. Her fees total $1.2 million.

“She also co-authored an editorial praising the pricing approach taken by a manufacturer with which she had a financial relationship, although the effectiveness of the diet drug was modest. Unlike the paper, the editorial did not disclose her ties.” Read more here.

(Source: Ed Silverman, STAT News, 10/10/21)